{"owner": "ArrayExpress Uploader", "ownerprofile_id": "arrayexpress_sid", "species": "human", "factors": [{"GSE7510GSM182021": {}}, {"GSE7510GSM182022": {}}, {"GSE7510GSM182023": {}}, {"GSE7510GSM182024": {}}, {"GSE7510GSM182025": {}}, {"GSE7510GSM182026": {}}, {"GSE7510GSM182027": {}}, {"GSE7510GSM182028": {}}], "id": 4912, "pop_total": 0, "platform": 4, "summary_wrapped": "Allogeneic peripheral blood stem cell transplantation (PBSCT) is indicated for the treatment of high-risk hematological malignancies, and...", "geo_gse_id": "E-GEOD-7510", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 0, "sample_count": 8, "tags": ["cancer", "cell", "dendritic", "disease", "genome", "organ", "peripheral", "peripheral blood stem cell", "stem cell"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "transcription-profiling-of-human-leukocytes-from-p", "geo_id_plat": "E-GEOD-7510_A-AFFY-44", "name": "Transcription profiling of human leukocytes from peripheral blood stem cell transplant patients to investigate acute graft versus host disease aGVHD", "created": "Sep.22, 2014", "summary": "Allogeneic peripheral blood stem cell transplantation (PBSCT) is indicated for the treatment of high-risk hematological malignancies, and in some cases is a cancer cure. A major complication associated with PBSCT (affecting approximately half of recipients) is acute graft-versus-host disease (aGVHD). In aGVHD, alloreactive donor T cells becoming activated by host dendritic cells (DC) in response to pro-inflammatory cytokines released during the conditioning regimen. The result is donor-derived CD4+ T helper-type 1 (Th1) cells maturing and subsequently imposing cytolytic effector responses on host tissues, resulting in multi-organ damage. Despite this well-defined pathophysiological mechanism, there are no definitive markers for predicting aGVHD development or progression to clinically advanced stages. In the current study, we enrolled 8 PBSCT recipients in an IRB-approved study and collected peripheral blood at the time to engraftment. Of these, four patients developed aGVHD within 5-10 days post transplant. The remaining four patients were aGVHD-free.  Using total RNA collected from whole blood leukocytes, we analyzed each recipient\u2019s gene expression profile on Affymetrix GeneChip Human Genome U133 Plus 2.0 microarrays. Experiment Overall Design: Samples 1-4 are control patients; 5-8 are aGVHD patients.  Peripheral blood was collected at engraftment and used for microarray analysis.  In analysing the data, the type of transplant (MUD, related) was used as a covariate to assess if there were significant changes in gene expression between the control (1-4) and aGVHD (5-8) groups, based on a 10% FDR with a pooled error estimate.", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-7510", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-7510/samples/"}